Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: Results of two randomized Phase IIA trials
Vanhoutte, Frédéric, Mazur, Minodora, Voloshyn, Oleksandr, Stanislavchuk, Mykola, Van der Aa, Annegret, Namour, Florence, Galien, René, Meuleners, Luc, van ‘t Klooster, GerbenLanguage:
english
Journal:
Arthritis & Rheumatology
DOI:
10.1002/art.40186
Date:
June, 2017
File:
PDF, 1014 KB
english, 2017